132 related articles for article (PubMed ID: 21755835)
1. A study of the methylation status of opioid binding protein/cell adhesion molecule-like gene in ovarian cancer using nested methylation-specific polymerase chain reaction detection.
Zhou F; Cao X; Liu M; Wang Y; Tao G
Clin Lab; 2011; 57(5-6):421-4. PubMed ID: 21755835
[TBL] [Abstract][Full Text] [Related]
2. Epigenetic and genetic alterations of p33ING1b in ovarian cancer.
Shen DH; Chan KY; Khoo US; Ngan HY; Xue WC; Chiu PM; Ip P; Cheung AN
Carcinogenesis; 2005 Apr; 26(4):855-63. PubMed ID: 15677627
[TBL] [Abstract][Full Text] [Related]
3. Opioid-binding protein/cell adhesion molecule-like (OPCML) gene and promoter methylation status in women with ovarian cancer.
Czekierdowski A; Czekierdowska S; Szymanski M; Wielgos M; Kaminski P; Kotarski J
Neuro Endocrinol Lett; 2006 Oct; 27(5):609-13. PubMed ID: 17159813
[TBL] [Abstract][Full Text] [Related]
4. KRAS and BRAF mutations in ovarian tumors: a comprehensive study of invasive carcinomas, borderline tumors and extraovarian implants.
Mayr D; Hirschmann A; Löhrs U; Diebold J
Gynecol Oncol; 2006 Dec; 103(3):883-7. PubMed ID: 16806438
[TBL] [Abstract][Full Text] [Related]
5. RPS6KA2, a putative tumour suppressor gene at 6q27 in sporadic epithelial ovarian cancer.
Bignone PA; Lee KY; Liu Y; Emilion G; Finch J; Soosay AE; Charnock FM; Beck S; Dunham I; Mungall AJ; Ganesan TS
Oncogene; 2007 Feb; 26(5):683-700. PubMed ID: 16878154
[TBL] [Abstract][Full Text] [Related]
6. Imprinted tumor suppressor genes ARHI and PEG3 are the most frequently down-regulated in human ovarian cancers by loss of heterozygosity and promoter methylation.
Feng W; Marquez RT; Lu Z; Liu J; Lu KH; Issa JP; Fishman DM; Yu Y; Bast RC
Cancer; 2008 Apr; 112(7):1489-502. PubMed ID: 18286529
[TBL] [Abstract][Full Text] [Related]
7. [Relation between DNA content in ovarian cystadenoma and its pathohistology].
Sun ZC
Zhonghua Fu Chan Ke Za Zhi; 1993 Dec; 28(12):731-3, 760-1. PubMed ID: 8137645
[TBL] [Abstract][Full Text] [Related]
8. Molecular abnormalities in ovarian carcinoma: clinical, morphological and therapeutic correlates.
Gurung A; Hung T; Morin J; Gilks CB
Histopathology; 2013 Jan; 62(1):59-70. PubMed ID: 23240670
[TBL] [Abstract][Full Text] [Related]
9. OPCML gene promoter methylation and gene expression in tumor and stroma cells of invasive cervical carcinoma.
Ye F; Zhang SF; Xie X; Lu WG
Cancer Invest; 2008 Jul; 26(6):569-74. PubMed ID: 18584347
[TBL] [Abstract][Full Text] [Related]
10. Prognostic value of opioid binding protein/cell adhesion molecule-like promoter methylation in bladder carcinoma.
Duarte-Pereira S; Paiva F; Costa VL; Ramalho-Carvalho J; Savva-Bordalo J; Rodrigues A; Ribeiro FR; Silva VM; Oliveira J; Henrique R; Jerónimo C
Eur J Cancer; 2011 May; 47(7):1106-14. PubMed ID: 21273058
[TBL] [Abstract][Full Text] [Related]
11. [Deletion of OPCML gene and promoter methylation in ovarian epithelial carcinoma].
Zhang J; Ye F; Chen HZ; Ye DF; Lu WG; Xie X
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2006 Apr; 28(2):173-7. PubMed ID: 16733898
[TBL] [Abstract][Full Text] [Related]
12. Expression and methylation status of 14-3-3 sigma gene can characterize the different histological features of ovarian cancer.
Kaneuchi M; Sasaki M; Tanaka Y; Shiina H; Verma M; Ebina Y; Nomura E; Yamamoto R; Sakuragi N; Dahiya R
Biochem Biophys Res Commun; 2004 Apr; 316(4):1156-62. PubMed ID: 15044106
[TBL] [Abstract][Full Text] [Related]
13. The role of p53 mutation in the carcinomas arising from endometriosis.
Akahane T; Sekizawa A; Purwosunu Y; Nagatsuka M; Okai T
Int J Gynecol Pathol; 2007 Jul; 26(3):345-51. PubMed ID: 17581423
[TBL] [Abstract][Full Text] [Related]
14. Allelotyping defines minimal imbalance at chromosomal region 17q25 in non-serous epithelial ovarian cancers.
Dion F; Mes-Masson AM; Seymour RJ; Provencher D; Tonin PN
Oncogene; 2000 Mar; 19(11):1466-72. PubMed ID: 10723138
[TBL] [Abstract][Full Text] [Related]
15. WT1 and WT1-AS genes are inactivated by promoter methylation in ovarian clear cell adenocarcinoma.
Kaneuchi M; Sasaki M; Tanaka Y; Shiina H; Yamada H; Yamamoto R; Sakuragi N; Enokida H; Verma M; Dahiya R
Cancer; 2005 Nov; 104(9):1924-30. PubMed ID: 16134181
[TBL] [Abstract][Full Text] [Related]
16. Association of decreased mitochondrial DNA content with ovarian cancer progression.
Wang Y; Liu VW; Xue WC; Cheung AN; Ngan HY
Br J Cancer; 2006 Oct; 95(8):1087-91. PubMed ID: 17047655
[TBL] [Abstract][Full Text] [Related]
17. [Hypermethylation of promoter region of RASSF1A gene in ovarian malignant epithelial tumors].
Ma L; Zhang JH; Liu FR; Zhang X
Zhonghua Zhong Liu Za Zhi; 2005 Nov; 27(11):657-9. PubMed ID: 16438885
[TBL] [Abstract][Full Text] [Related]
18. [Correlations of CpG island methylator phenotype and OPCML gene methylation to carcinogenesis of hepatocellular carcinoma].
Liu WJ; Wang L; Wang JP; Li JQ; Zhang CQ; Zheng L; Yuan YF
Ai Zheng; 2006 Jun; 25(6):696-700. PubMed ID: 16764763
[TBL] [Abstract][Full Text] [Related]
19. Loss of heterozygosity at chromosome 9q22-31 is a frequent and early event in ovarian tumors.
Byrom J; Mudaliar V; Redman CW; Jones P; Strange RC; Hoban PR
Int J Oncol; 2004 May; 24(5):1271-7. PubMed ID: 15067351
[TBL] [Abstract][Full Text] [Related]
20. Promoter methylation of sFRP5 in patients with ovarian clear cell adenocarcinoma.
Ho CM; Lai HC; Huang SH; Chien TY; Lin MC; Chang SF
Eur J Clin Invest; 2010 Apr; 40(4):310-8. PubMed ID: 20486992
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
